Anoctamin 5 promotes osteosarcoma development by increasing degradation of Nel-like proteins 1 and 2

Runsang Pan¹, Qiaoying Lu¹, Chong Ren¹, Hao Li¹, Fanqiang Zeng¹, Xiaobin Tian², Houping Chen¹

¹Department of Orthopedics, Guiyang Maternal and Child Health-Care Hospital, Guiyang 550009, Guizhou, China
²Department of Orthopedics, The Affiliated Hospital of Guizhou Medical University, Guiyang 550009, Guizhou, China

Correspondence to: Xiaobin Tian, Houping Chen; email: txb6@vip.163.com; houpingchen@126.com, https://orcid.org/0000-0002-3548-9868

Keywords: osteosarcoma, ANO5, NELL1, NELL2

Received: March 18, 2021 Accepted: May 20, 2021 Published: July 9, 2021

Copyright: © 2021 Pan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Anoctamin 5 (ANO5) is a member of the Anoctamin (ANO) family of calcium-activated chloride channels. Although ANO5 expression is upregulated in various cancers, its role in osteosarcoma remains largely unknown. In this study, bioinformatics analysis, western blot, and immunohistochemical staining revealed that ANOS was upregulated in osteosarcoma cell lines and osteosarcoma tissues, and ANO5 expression was positively associated with tumor size, tumor grade, and metastasis. Functional experiments demonstrated that inhibition of ANO5 decreased, while ANO5 overexpression increased, osteosarcoma cell proliferation and mobility in vitro. Immunoprecipitation, western blot, and confocal microscopy experiments showed that ANO5 bound to and promoted the degradation of Nel-like proteins 1 (NELL1) and 2 (NELL2). Moreover, a subcutaneous tumor transplantation model revealed that ANO5 knockdown reduced osteosarcoma cell proliferation and increased NELL1 and NELL2 expression in vivo. Finally, rescue experiments showed that knockdown of NELL1 or NELL2 reversed the inhibitory effects of ANO5 knockdown on osteosarcoma cell proliferation and migration. These results demonstrated that upregulation of ANO5 promoted osteosarcoma development by decreasing the stability of the NELL1 and NELL2 proteins and that ANO5 may be an effective target for the treatment of osteosarcoma.

INTRODUCTION

Osteosarcoma is a common and very aggressive type of bone malignancy [1]. Despite advances in diagnosis and therapy, the overall prognosis of osteosarcoma patients remains poor. Moreover, recurrent metastatic osteosarcoma is observed in more than 80% of patients after surgery [2, 3]. It is therefore urgent to identify regulators of osteosarcoma progression in order to improve therapies for this type of cancer.

The Anoctamin (ANO) family, also called the transmembrane member 16 (TMEM16) family, is a class of calcium-activated chloride channels that regulate various biological functions, including ion transport and maintenance of membrane proteins [4, 5]. ANO family members are up-regulated in and promote the development of cancers. For example, ANO1 levels were increased in gastric cancer tissues and were positively associated with TNM stage [6]. Additionally, esophageal squamous cell carcinoma patients with higher ANO1 levels had poorer prognoses [7]. ANO9 was highly expressed in pancreatic cancer and promoted the metastasis of pancreatic cancer cells by increasing epithelial growth factor receptor expression [8]. Finally, ANO6 activated the ERK pathway and promoted glioma development [9].

Neural epidermal growth factor-like (Nel) proteins are a class of glycoproteins that are very similar in structure to thrombospondin1 and are secreted into the extracellular matrix. At present, two Nel family
members, NELL1 and NELL2, have been identified in mammals [10]. NELL1 and NELL2 show greater than 50% homology in their amino acid sequences and map to chromosomes 11p15.1 and 12q12, respectively [11]. Physiologically, NELL1 and NELL2 promote differentiation during osteogenesis and osteocyte proliferation [12]. NELL1 expression is typically reduced in osteosarcoma compared with benign tumor tissues, indicating that it may act as a tumor suppressor [13]. However, little is known about the regulatory mechanisms associated with NELL proteins.

In this study, we found that ANO family member ANO5 was highly expressed in osteosarcoma tissues and cell lines and that it promoted the proliferation and metastasis of osteosarcoma cells by increasing the degradation of NELL1 and NELL2.

RESULTS

ANO5 was upregulated in osteosarcoma

First, we analyzed gene expression in the GSE32395 dataset, which contains the normal osteoblast cell line hFOB 1.19, the normal bone marrow stromal cell line L87/4, and seven osteosarcoma cell lines (HOS, HOS-58, U2OS, Saos2, MNNG, SJSA, and MG63). The results showed that ANO5 gene expression was markedly upregulated in osteosarcoma cell lines (Figure 1A). Using qRT-PCR and western blot, we found that ANO5 mRNA and protein levels were both elevated in osteosarcoma cells (U2OS, MG63, HOS, and Saos2) compared to the normal osteoblast cell line hFOB 1.19 (Figure 1B–1D). Furthermore, immunohistochemical staining of ANO5 in 40 paired osteosarcoma and adjacent normal tissues indicated that ANO5 was also elevated in osteosarcoma tissues (Figure 1E). Finally, we found that high ANO5 expression was positively associated with tumor size, tumor grade, and metastasis (Table 1). Together, these results indicate that ANO5 may act as an oncogene in osteosarcoma.

Inhibition of ANO5 reduced osteosarcoma cell proliferation and metastasis in vitro

To examine the role of ANO5 in osteosarcoma, short hairpin RNAs were used to established ANO5 knockdown cells (Figure 2A, 2B). CCK-8 and EDU

Figure 1. ANO5 was upregulated in osteosarcoma. (A) A volcano plot showed that the ANO5 gene was significantly upregulated in osteosarcoma cells. (B) qRT-PCR indicated that ANO5 was upregulated in osteosarcoma cells (U2OS, MG63, HOS, and Saos2) compared to the normal osteoblast cell line hFOB 1.19. (C, D) Western blot indicated that ANO5 was upregulated in osteosarcoma cells (U2OS, MG63, HOS, and Saos2) compared to the normal osteoblast cell line hFOB 1.19. (E) IHC demonstrated that ANO5 was more highly expressed in osteosarcoma tissues than in adjacent normal tissues. *, P<0.05; **, P<0.01.
**Table 1. Relationships between ANO5 expression and age, gender, tumor size, tumor grade, and metastasis in osteosarcoma patients were evaluated using a Chi-square test.**

| Parameters          | ANO5 expression | P value |
|---------------------|-----------------|---------|
|                     | High | Low |        |
| Gender              | 0.996 |
| Male                | 13   | 14  |        |
| Female              | 7    | 6   |        |
| Age                 | 0.995 |
| >19                 | 6    | 5   |        |
| ≤19                 | 14   | 15  |        |
| Tumor size (cm)     | 0.022 |
| >5                  | 16   | 8   |        |
| ≤5                  | 4    | 12  |        |
| Tumor stage         | 0.019 |
| I + IIA             | 3    | 11  |        |
| IIB/III             | 17   | 9   |        |
| Metastasis          | 0.025 |
| Yes                 | 15   | 7   |        |
| No                  | 5    | 13  |        |

assays showed that inhibition of ANO5 decreased HOS and Saos2 cell proliferation (Figure 2C–2F). A wound healing assay showed that inhibition of ANO5 significantly suppressed the migration of HOS and Saos2 cells (Figure 2G). Moreover, a transwell assay indicated that suppression of ANO5 decreased HOS and Saos2 cell invasion (Figure 2H).

**Overexpression of ANO5 increased osteosarcoma proliferation and metastasis in vitro**

Next, we used an ANO5 overexpression lentivirus to generate ANO5 overexpression cell lines (Figure 3A, 3B). CCK-8 and EDU assays indicated that ANO5 overexpression increased the proliferation rate of HOS and Saos2 cells (Figure 3C–3F). Similarly, wound healing assays demonstrated that overexpression of ANO5 promoted migration in HOS and Saos2 cells (Figure 3G). Furthermore, increased ANO5 expression promoted invasion in HOS and Saos2 cells (Figure 3H). Taken together, these in vitro experiments indicated that ANO5 acts as oncogene by promoting osteosarcoma cell proliferation and metastasis.

**ANO5 bound to and increased degradation of NELL1 and NELL2**

To explore how ANO5 promotes osteosarcoma development, the online tool STRING was used to identify proteins that interact with ANO5. NELL1 and NELL2, which act as suppressors in various types of cancer including osteosarcoma, were identified as proteins that interact with ANO5 (Figure 4A). We found that NELL1 and NELL2 protein levels were decreased in ANO5 overexpression cells and were increased in ANO5 knockdown cells (Figure 4B, 4C). In addition, immunoprecipitation demonstrated that ANO5 directly interacted with NELL1 and NELL2 (Figure 4D). Moreover, a cycloheximide (CHX, 10 μM) was used and the result indicated that overexpression of ANO5 increased the degradation rates of NELL1 and NELL2 (Figure 4E). Furthermore, confocal microscopy demonstrated that ANO5 was colocalized with NELL1 and NELL2 in osteosarcoma cells (Figure 4F).

**Suppression of ANO5 decreased osteosarcoma cell proliferation and increased NELL1 and NELL2 expression in vivo**

A subcutaneous tumor transplantation model was then employed to examine the effects of ANO5 on osteosarcoma cell proliferation and NELL1 and NELL2 expression in vivo. The results showed that inhibition of ANO5 markedly reduced osteosarcoma cell proliferation rates in vivo (Figure 5A, 5B). Furthermore, both NELL1 and NELL2 were increased in tumor tissues with lower ANO5 expression, while the expression of Ki67 (a biomarker for proliferation) was
Figure 2. Inhibition of ANOS decreased osteosarcoma cell proliferation and metastasis in vitro. (A, B) qRT-PCR and western blot were used to determine the transfection efficiency of targeted ANOS shRNA. (C) A CCK-8 assay was used to evaluate the effects of ANOS knockdown on osteosarcoma cell proliferation. (D–F) EDU assays showed that proliferation rates were reduced in ANOS knockdown osteosarcoma cells. (G) A wound healing assay was used to examine the effect of ANOS inhibition on osteosarcoma cell migration. (H) A transwell assay was used to determine the effect of ANOS knockdown on osteosarcoma cell invasion. *, P<0.05; **, P<0.01.
Figure 3. Overexpression of ANOS increased osteosarcoma cell proliferation and metastasis in vitro. (A, B) qRT-PCR and western blot were used to evaluate the transfection efficiency of ANOS overexpression lentivirus. (C) A CCK-8 assay was used to examine the effects of ANOS overexpression on osteosarcoma cell proliferation. (D–F) EDU assays showed that proliferation rates were higher in ANOS overexpression osteosarcoma cells. (G) A wound healing assay was used to determine the effect of ANOS overexpression on osteosarcoma cell migration. (H) A transwell assay was used to determine the effect of ANOS overexpression on osteosarcoma cell invasion. *, P<0.05; **, P<0.01.
decreased (Figure 5C). Taken together, these findings demonstrate that suppression of ANO5 decreased osteosarcoma cell proliferation and increased NELL1 and NELL2 expression in vivo.

**Inhibition of NELL1 or NELL2 reversed the inhibitory effects of ANO5 knockdown in osteosarcoma cells**

To determine whether NELL1 and NELL2 were involved in ANO5-induced osteosarcoma, we inhibited NELL1 or NELL2 expression in ANO5 knockdown cells (Figure 6A). A CCK-8 assay indicated that suppression of either NELL1 or NELL2 in ANO5 knockdown cells significantly reversed ANO5 suppression-induced inhibition of cell proliferation (Figure 6B). Similarly, ANO5 knockdown cells with NELL1 or NELL2 inhibition showed higher invasive ability than cells without NELL1 or NELL2 inhibition (Figure 6C).

**DISCUSSION**

Osteosarcoma is a severe bone tissue malignancy characterized by an extremely poor prognosis. Because
of the high efficacy of targeted gene therapy, identification of the molecular mechanisms underlying osteosarcoma progression is particularly important [14]. Here, we explored the biological functions and molecular mechanisms of ANO5 in osteosarcoma. We found that ANO5 promoted the proliferation and metastasis of osteosarcoma by increasing the degradation of NELL1 and NELL2.

Previous studies on the role of ANO5 in cancer development have reported contradictory results. Yu et al. demonstrated that ANO5 was downregulated in prostate cancer and lower expression of ANO5 predicted poorer prognosis [15]. Similarly, Chang et al. found that ANO5 suppressed the mobility of thyroid cancer cells by decreasing JAK/STAT pathway activity [16]. However, Song et al. showed that ANO5 expression was increased in pancreatic cancer and promoted cell proliferation and metastasis [17]. In addition, Ishaque et al. showed that ANO5 expression was positively associated with metastasis of colorectal cancer [18]. In the current study, bioinformatic analysis, western blots, and immunohistochemical staining demonstrated that ANO5 expression was higher in osteosarcoma tissues and cell lines than in adjacent tissues and hFOB1.19 cells. High ANO5 expression was positively associated with tumor size, tumor grade, and metastasis. Furthermore, by performing loss and gain of function experiments, we found that ANO5 promoted proliferation and metastasis of osteosarcoma cells in vitro. To our knowledge, these are the first findings to indicate that ANO5 may act as onco-gene in osteosarcoma.

The biological functions of a protein are typically a result of its interactions with other proteins. The STRING online database can predict protein-protein association networks and perform functional enrichment analysis [19, 20]. The STRING interaction network for ANO5 indicated that it interacted with NELL1 and NELL2, suggesting that these proteins may play a role in ANO5-induced proliferation and metastasis in osteosarcoma. In previous studies, NELL1 and NELL2, which act as tumor suppressors, were downregulated in a variety of cancers including osteosarcoma. For example, Peters et al. demonstrated that lower NELL1 expression predicted advanced metastasis in patients with renal cell cancer [21]. Additionally, Maeda et al. showed that both NELL1 and NELL2 were downregulated in glioma [22]. Furthermore,
hypermethylation of NELL1 and NELL2, which decreased their transcription, was common in cancer [23]. Here, we found that ANO5 overexpression reduced, while inhibition of ANO5 increased, NELL1 and NELL2 expression. Previous research indicates that proteins can regulate the stability of their binding partner proteins. We found that ANO5 directly bound to NELL1 and NELL2, and ANO5 overexpression increased the degradation of both NELL1 and NELL2. Inhibition of ANO5 increased NELL1 and NELL2 expression in vivo and decreased tumor proliferation. Suppression of NELL1 or NELL2 in ANO5 knockdown cells reversed the anti-proliferation effects of ANO5 inhibition. To our knowledge, this is the first evidence that NELL1 and NELL2 are involved in the biological functions of ANO5. We also identified a novel mechanism in addition to DNA hypermethylation by which the tumor suppressors NELL1 and NELL2 were downregulated in cancer tissues.

Taken together, our current results demonstrate that ANO5 acted as a novel oncogene in osteosarcoma. ANO5 expression was elevated in osteosarcoma and promoted the development of osteosarcoma cells by increasing degradation of the tumor suppressors NELL1 and NELL2. ANO5 might therefore be a potential target for osteosarcoma therapy.

Figure 6. NELL1 and NELL2 knockdown suppressed ANO5-induced inhibition of proliferation and invasion. (A) Western blot was used to detect the effects of NELL1 and NELL2 inhibition on expression of ANO5, NELL1, and NELL2 in ANO5 knockdown cells. (B) CCK-8 was used to detect the effects of NELL1 and NELL2 knockdown on ANO5 suppression-induced inhibition of cell proliferation. (C) A transwell assay was used to detect the effects of NELL1 and NELL2 knockdown on ANO5 suppression-induced inhibition of cell invasion. *, P<0.05; **, P<0.01.
MATERIALS AND METHODS

Patients and tissue specimens

This study was approved by the Affiliated Hospital of Guizhou Medical University. A total of 40 paired osteosarcoma tissues and adjacent normal tissues were collected from the patients (mean age: 19.43 ± 7.27 years; male/female: 27/13) at the pathology department, Affiliated Hospital of Guizhou Medical University, China, between March 2018 and May 2020. The inclusion criteria were as follows: (1) tissues were obtained during surgery and osteosarcoma was diagnosed by two pathologists; (2) patients were diagnosed and treated for the first time; (3) patients agreed to participate in the study. The exclusion criteria were as follows: (1) patients with other malignancies; (2) patients with other systemic diseases; (3) patients who had received treatment prior to admission; (4) patients who did not agree to participate. None of the patients received chemotherapy or radiotherapy before sample collection, and all patients involved in the current study provided written informed consent.

Bioinformatics analysis

The gene expression profile GSE32395, which contains data from the normal osteoblast cell line hFOB 1.19, the normal bone marrow stromal cell line L87/4, and seven osteosarcoma cell lines (HOS, HOS-58, U2OS, Saos2, MNNG, SJSA, and MG63) was downloaded from GENE EXPRESSION OMNIBUS (GEO, URL: https://www.ncbi.nlm.nih.gov/geo/). After standardization, the edgeR package was used to analyze differences in gene expression in R software (Version: 4.0.2); the threshold was set at LogFC>2, and an adjusted P value<0.05 was considered significant. Differentially expressed genes were shown in a volcano plot. The STRING website (URL: https://string-db.org/) was used to identify proteins that interact with ANO5 using a protein-protein interaction network.

Cell culture and transfection

The normal osteoblast cell line hFOB 1.19 and four osteosarcoma cell lines (U2OS, MG63, HOS, and Saos2) were obtained from ATCC (USA). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Boster, Wuhan, China) containing 10% fetal bovine serum (FBS; Hyclone, USA) at 37°C in an environment with 5% CO2. ANO5 overexpression lentiviruses, negative control lentiviruses (NC), short hairpin RNA (shRNA) against ANO5 (sh-ANO5), and scramble shRNA (sh-scramble) were purchased from Genechem (Shanghai, China). Small interfering RNA (siRNA) targeting NELL1 and NELL2 and corresponding negative control siRNAs were purchased from GeneCopoeia (Guangzhou, China). The sequences were as follows: sh-ANO5, GCUGUAGUGCUUA GCUUTT; sh-scramble, UUCUCCAGCUGUCACG UTT; NELL1 siRNA, GAGCCTGGTCAAGGAATA; NELL2 siRNA, GGACGAAAGCCUUCUCCUU. Transfection of lentiviruses, shRNAs, and siRNAs was performed using Lipo2000 (Invitrogen, USA) according to the manufacturer's instruction. To promote stable expression, cells were then incubated continuously with 1 μg/mL puromycin for 12 days.

qRT-PCR

Total RNA was isolated from osteosarcoma tissues and cells using TRIzol (Takara, Japan). cDNA was synthesized from 2 μg isolated mRNA using Hifair® II 1st Strand cDNA Synthesis SuperMix (Yeasen, Shanghai, China). The Hifair® III One Step RT-qPCR SYBR Green Kit (Yeasen, Shanghai, China) was used for qPCR. The qPCR reaction system included the following: 1 μL cDNA template, 0.25 μL forward primer, 0.25 μL reverse primer, 6.75 μL SYBR Green reagent, and 4.25 μL dH2O. The qPCR program consisted of 5 min at 95°C and 35 cycles of 30 seconds at 95°C, 30 seconds at 65°C, and 1 minute at 70°C. β-actin was used as the reference gene for determining relative expression of the target gene. ANO5 and β-actin primers were as follows: ANO5 forward primer, 5'-GGGCGGGTTGTGTTTCCTTAAAC-3'; ANO5 reverse primer, 5'-CCTGCAAACTCTGCTGCCTTTC-3'; β-actin forward primer, 5'-CATGTACGTTGCCT TCAGGGC-3'; β-actin reverse primer, 5'-CTCTCTAAT GTCTCGGCAC TAT-3'.

Western blot

Whole protein was isolated from osteosarcoma cells using RIPA reagent (Boster, Wuhan, China) containing 10% PMSF inhibitor. Protein samples were separated using 10% SDS-PAGE at 100 V for 2 h and transferred into PVDF membranes at 310 mA for 2 h. After blocking with 10% non-fat milk for 2 h, primary antibodies against ANO5 (dilution 1:1000; cat no. PA5-109393, Sigma, USA), NELL1 (dilution 1:500; cat no. PA5-27958, Sigma, USA), NELL2 (dilution 1:500; cat no. PA5-42910, Sigma, USA), and β-actin (dilution 1:2000; cat no. 20536-1-AP, Proteintech, Wuhan, China) were added and incubated at 4°C overnight. The membranes were then incubated with secondary antibodies after washing three times with TBST. Finally, ECL reagent was used to visualize the bands, and β-actin was used as a loading control to calculate relative expression of target proteins.
**Immunohistochemistry (IHC)**

Osteosarcoma tissues and adjacent tissues were sliced into 2 µm thick sections and then incubated at 65°C for 2 h. The sections were then dewaxed in xylene and rehydrated via an ethyl alcohol concentration gradient. Antigen retrieval was performed via a high-pressure method with an EDTA reagent (Boster, Wuhan, China). After blocking using H₂O₂ and 5% BSA, primary antibodies against ANO5 (dilution 1:200; cat no. PA5-63619, Sigma, USA), NELL1 (dilution 1:200; cat no. PA5-27958, Sigma, USA), NELL2 (dilution 1:200; cat no. PA5-57373, Sigma, USA), and KI67 (dilution 1:200; cat no. PA5-19462, Sigma, USA) were added and incubated at 4°C overnight. Then, secondary antibodies were added and incubated at room temperature for 2 h. Finally, after staining with DAB (Servicebio, Wuhan, China), hematoxylin was used to stain cell nuclei and images were obtained using a light microscope (200×, Nikon, Japan).

**Cell count kit-8 (CCK-8) assay**

A total of 5×10³ HOS and Saos2 cells were plated into the wells of a 96 well-plate. After 24 h, 48 h, or 72 h, 10 µL of CCK-8 reagent (Boster, Wuhan, China) was added to each well. After culturing for an additional 2 h at 37°C, the absorbance of each well at 450 nm was measured.

**5-Ethynyl-2 (EDU) assay**

Osteosarcoma cells were added to 6-well plates (5×10⁵ cells/well) with DMEM (10% FBS) and cultured for 24 h. Then, the cells were incubated with 50 µM EdU reagent (Beyotime, Suzhou, China) at 37°C for 2.5 h, fixed with 4% paraformaldehyde (Servicebio, Wuhan, China) and 0.5% Triton reagent (Servicebio, Wuhan, China) for 30 min, and stained with 1x Apollo® reaction cocktail (Beyotime, Suzhou, China) for 40 min. Finally, cell nuclei were stained with DAPI (Servicebio, Wuhan, China), and cells were visualized using a fluorescence microscope (Nikon, Japan).

**Wound healing assay**

A total of 5×10⁵ osteosarcoma cells were plated in 6-well plates and allowed to reach 95% confluence. Then, a 200 µL pipette tip was used to form a wound by scraping. After washing with PBS three times to remove floating cells, wound healing was assessed at 0 h and 24 h using a light microscope (40×). Migration ability was calculated according to the following formula: cell migration (%) = (area in treatment group at 0 h – area in treatment group at 24 h) / (area in control group at 0 h – area in control group at 24 h) × 100%.

**Transwell assay**

A total of 2×10⁵ osteosarcoma cells were plated in the upper chambers of a transwell plate (0.8µm, Corning, USA) containing Matrigel (Corning, USA) with 300 µL of FBS-free DMEM medium. Then, 700 µL of DMEM medium containing 10% FBS was placed in the lower transwell chamber as a chemoattractant. After culturing for 24 h, the transwells were fixed, stained with 1% crystal violet for 30 min, and visualized using a light microscope (100×). The invasive ability of cells was evaluated by the average number of invaded cells in five random fields.

**Immunoprecipitation**

Cells were lysed in weak RIPA buffer (Boster, Wuhan, China) containing 1% PMSF. The liquid was centrifuged and the protein was collected. Then, anti-ANO5 (dilution 1:50) antibody and IgG (dilution 1:50; Beyotime; Hangzhou, China) were added for 6 h. A/G-agarose beads (MCE, Wuhan, China) were then added and incubated for 3h. After washing three times with PBS, isolated immunoprecipitates attached to the beads were collected and analyzed using western blot.

**Confocal microscopy**

Osteosarcoma cells were injected into a confocal dish (5×10⁵ cells/well) with DMEM (10% FBS) and cultured for 24 h. Then, the cells were fixed and treated with 0.5% Triton reagent for 8 min at room temperature. After blocking with 5% BSA, the cells were incubated with anti-ANO5, anti-NELL1, and anti-NELL2 antibodies at 4°C overnight. After incubating with secondary antibodies, nuclei were stained with DAPI (Servicebio, Wuhan, China), and the cells were visualized using a confocal microscope (Nikon, Japan).

**Animal experiments**

Ten female BALB/c nude mice (4-6 weeks old; weight 16-18 g) were obtained from Beijing HuaFukang Biotech (URL: http://www.hfkbio.com/). The mice were housed at 23–24°C, and the light-dark cycle was set at 12 h intervals. A total of 5 ×10⁶ HOS cells with ANO5 inhibition or NC HOS cells were injected subcutaneously into the right armpits of the mice (n=5 mice per group). Tumor proliferation was evaluated every three days, and the formula for calculating tumor volume was (length×width²)/2. After 30 days, the mice were sacrificed, and tumors were dissected to perform IHC. The animal experiments in this study were approved by the Animal Ethics Committee of Guizhou Medical University.
Data analysis

All data were analyzed using SPSS 20.0 software (IBM Corp., USA). ANOVA with Bonferroni’s post hoc test was used to analyze differences between multiple groups. T-tests were used to examine differences between two groups. P<0.05 was set as the cut-off for statistical significance.

Data availability

Data collected in this study are available from the corresponding author upon request.

AUTHOR CONTRIBUTIONS

Houping Chen and Xiaobin Tian designed the experiments and wrote the manuscript; Runsang Pan, Qiaoqing Lu, Chong Ren, Hao Li, and Fanqiang Zeng performed and analyzed the experiments. All authors read and approved the final version of the article.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

The present study was funded by The National Natural Science Foundation of China (82060491) and the Guiyang High-level Innovative Youth Health Talents Training Program Project (2020 Zhuweijian Technology Contract No. 018).

REFERENCES

1. Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, Rizvanov AA. Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020; 38:259–69. https://doi.org/10.1080/07357907.2020.1768401 PMID:32400205

2. Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther. 2020; 20:415–28. https://doi.org/10.1080/14737140.2020.1760848 PMID:32379504

3. Reed DR, Hingorani P, Anderson PM. Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease. Adv Exp Med Biol. 2020; 1257:85–94. https://doi.org/10.1007/978-3-030-43032-0_8 PMID:32483733

4. Lee BC, Khelashvili G, Falzone M, Menon AK, Weinstein H, Accardi A. Gating mechanism of the extracellular entry to the lipid pathway in a TMEM16 scramblase. Nat Commun. 2018; 9:3251. https://doi.org/10.1038/s41467-018-05724-1 PMID:30108217

5. Phuong TT, An J, Park SH, Kim A, Choi HB, Kang TM. Deficiency of Anoctamin 5/TMEM16E causes nuclear positioning defect and impairs Ca2+ signaling of differentiated C2C12 myotubes. Korean J Physiol Pharmacol. 2019; 23:539–47. https://doi.org/10.4196/kjpp.2019.23.6.539 PMID:31680776

6. Zeng X, Pan D, Wu H, Chen H, Yuan W, Zhou J, Shen Z, Chen S. Transcriptional activation of ANO1 promotes gastric cancer progression. Biochem Biophys Res Commun. 2019; 512:131–36. https://doi.org/10.1016/j.bbrc.2019.03.001 PMID:30871776

7. Yu Y, Cao J, Wu W, Zhu Q, Tang Y, Zhu C, Dai J, Li Z, Wang J, Xue L, Zhen F, Liu J, Huang C, et al. Genomewide copy number variation analysis identified ANO1 as a novel oncogene and prognostic biomarker in esophageal squamous cell cancer. Carcinogenesis. 2019; 40:1198–208. https://doi.org/10.1093/carcin/bgz077 PMID:31050728

8. Jun I, Park HS, Piao H, Han JW, An MJ, Yun BG, Zhang X, Cha YH, Shin YK, Youk Ji, Jung J, Gee HY, Park JS, et al. ANO9/TMEM16j promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Br J Cancer. 2017; 117:1798–809. https://doi.org/10.1038/bjc.2017.355 PMID:29024940

9. Xuan ZB, Wang YJ, Xie J. ANO6 promotes cell proliferation and invasion in glioma through regulating the ERK signaling pathway. Onco Targets Ther. 2019; 12:6721–31. https://doi.org/10.2147/OTT.S211725 PMID:31692479

10. Yamamoto N, Kashiwagi M, Ishihara M, Kojima T, Maturana AD, Kuroda K, Niimi S, Kojima T. Deficiency of Anoctamin 5/TMEM16E causes nuclear positioning defect and impairs Ca2+ signaling of differentiated C2C12 myotubes. Korean J Physiol Pharmacol. 2019; 23:539–47. https://doi.org/10.4196/kjpp.2019.23.6.539 PMID:31680776

11. Nakamura R, Nakamoto C, Obama H, Durward E, Nakamoto M. Structure-function analysis of Nel, a thrombospondin-1-like glycoprotein involved in neural development and functions. J Biol Chem. 2012; 287:3282–91. https://doi.org/10.1074/jbc.M111.281485 PMID:22157752
12. Xue J, Peng J, Yuan M, Wang A, Zhang L, Liu S, Fan M, Wang Y, Xu W, Ting K, Zhang X, Lu S. NELL1 promotes high-quality bone regeneration in rat femoral distraction osteogenesis model. Bone. 2011; 48:485–95. https://doi.org/10.1016/j.bone.2010.10.166 PMID:20959151

13. Shen J, LaChaud G, Shrestha S, Asatryan G, Zhang X, Dry SM, Soo C, Ting K, James AW. NELL-1 expression in tumors of cartilage. J Orthop. 2015 (Suppl 2); 12:S223–29. https://doi.org/10.1016/j.jpo.2015.10.001 PMID:27047227

14. Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021; 10:172. https://doi.org/10.3390/cells10010172 PMID:33467756

15. Yu CC, Chen LC, Huang CY, Lin VC, Lu TL, Lee CH, Huang SP, Bao BY. Genetic association analysis identifies a role for ANO5 in prostate cancer progression. Cancer Med. 2020; 9:2372–78. https://doi.org/10.1002/cam4.2909 PMID:32027096

16. Chang Z, Cai C, Han D, Gao Y, Li Q, Feng L, Zhang W, Zheng J, Jin J, Zhang H, Wei Q. Anoctamin5 regulates cell migration and invasion in thyroid cancer. Int J Oncol. 2017; 51:1311–19. https://doi.org/10.3892/ijo.2017.4113 PMID:28902351

17. Song HY, Zhou L, Hou XF, Lian H. Anoctamin 5 regulates cell proliferation and migration in pancreatic cancer. Int J Clin Exp Pathol. 2019; 12:4263–70. PMID:31933826

18. Ishaque N, Abba ML, Hauser C, Patil N, Paramasivam N, Huebschmann D, Leupold JH, Balasubramanian GP, Kleinheinz K, Toprak UH, Hutter B, Benner A, Shavinskaya A, et al. Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nat Commun. 2018; 9:4782. https://doi.org/10.1038/s41467-018-07041-z PMID:30429477

19. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003; 31:258–61. https://doi.org/10.1093/nar/gkg034 PMID:12519996

20. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47:D607–13. https://doi.org/10.1093/nar/gky1131 PMID:30476243

21. Peters I, Dubrowinska N, Hennenlotter J, Antonopoulos WI, Von Klot CA, Tezval H, Stenzl A, Kuczky MA, Serth J. DNA methylation of neural EGFLike 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients. Oncol Rep. 2018; 40:3861–68. https://doi.org/10.3892/or.2018.6732 PMID:30272321

22. Maeda K, Matsuhashi S, Tabuchi K, Watanabe T, Katagiri T, Oyasu M, Saito N, Kuroda S. Brain specific human genes, NELL1 and NELL2, are predominantly expressed in neuroblastoma and other embryonal neuroepithelial tumors. Neurol Med Chir (Tokyo). 2001; 41:582–88. https://doi.org/10.2176/nmc.41.582 PMID:11803583

23. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton JP, Kan T, Olaru A, David S, Agarwal R, Abraham JM, et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007; 26:6332–40. https://doi.org/10.1038/sj.onc.1210461 PMID:17452981